Table 1 Patient characteristics
Patients ( N =41) | ||
|---|---|---|
N | % | |
Age (years) | ||
Median | 58 | |
Range | 40–75 | |
ECOG performance status | ||
0 | 39 | 95 |
1 | 2 | 5 |
2 | 0 | 0 |
Histology | ||
Ductal infiltrating carcinoma | 37 | 90 |
Lobular infiltrating carcinoma | 4 | 10 |
ER expression (IHC) | ||
Positive | 27 | 66 |
Negative | 14 | 34 |
HER-2 expression (IHC) | ||
3+ | 5 | 12 |
Negative | 22 | 54 |
Unknown | 14 | 34 |
Prior adjuvant therapy | ||
Yes | 30 | 73 |
No | 11 | 27 |
Prior adjuvant chemotherapy | 30 | 73 |
Prior adjuvant anthracyclines | 22 | 54 |
Prior adjuvant taxanes | 6 | 15 |
Prior adjuvant hormonotherapy (tamoxifen) | 24 | 59 |
Dominant sites of disease | ||
Visceral | 34 | 83 |
Soft tissue (lymph nodes and bone sites)a | 7 | 17 |
